FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903826135> ?p ?o ?g. }

• W2903826135 abstract "<h3>Background</h3> Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand Pam3CSK4 to synthetic long peptides (SLPs) was shown to strongly enhance the induction of antitumor immunity. To further improve cancer vaccination, we have previously shown that the novel TLR2-L Amplivant (AV), a modified Pam3CSK4, potentiates the maturation effects on murine DCs. In the current study, we further assessed the immunological properties of AV. <h3>Methods</h3> Naïve mice were vaccinated with a conjugate of either Pam3CSK4 or AV and an SLP to assess specific T cell priming efficiency in vivo. The potency of AV and Pam3CSK4, either as free compounds or conjugated to different SLPs, to mature murine DCs was compared by stimulating murine dendritic cells overnight followed by ELISA and flow cytometry analysis. Murine tumor experiments were carried out by vaccinating mice carrying established HPV16 E6 and E7-expressing tumors and subsequently analyzing myeloid and lymphoid cells infiltrating the tumor microenvironment. Furthermore, tumor outgrowth after vaccination was monitored to enable comparison of the efficiency to induce antitumor immunity by Pam3CSK-SLP and AV-SLP conjugates. To enhance therapeutic efficacy, AV-SLP conjugate vaccination was combined with ablative therapies to assess whether synergism between such therapies would occur. <h3>Results</h3> SLPs conjugated to AV induce stronger DC maturation, in vivo T cell priming and antitumor immunity compared to conjugates with Pam3CSK4. Interestingly, AV-SLP conjugates modulate the macrophage populations in the tumor microenvironment, correlating with a therapeutic effect in an aggressive murine tumor model. The potency of AV-SLP conjugates in cancer vaccination operates optimally in combination with chemotherapy or photodynamic therapy. <h3>Conclusion</h3> These data allow further optimization of vaccination-based immunotherapy of cancer by use of the improved TLR2-ligand Amplivant." @default.
• W2903826135 created "2018-12-22" @default.
• W2903826135 creator A5012656051 @default.
• W2903826135 creator A5035490415 @default.
• W2903826135 creator A5035565968 @default.
• W2903826135 creator A5054122862 @default.
• W2903826135 creator A5054893411 @default.
• W2903826135 creator A5061083695 @default.
• W2903826135 creator A5071090402 @default.
• W2903826135 creator A5081264511 @default.
• W2903826135 creator A5087405110 @default.
• W2903826135 creator A5088802895 @default.
• W2903826135 date "2018-12-01" @default.
• W2903826135 modified "2023-10-16" @default.
• W2903826135 title "Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication" @default.
• W2903826135 cites W1522781268 @default.
• W2903826135 cites W1848628272 @default.
• W2903826135 cites W1918446688 @default.
• W2903826135 cites W1949342640 @default.
• W2903826135 cites W1970172717 @default.
• W2903826135 cites W1978146796 @default.
• W2903826135 cites W1988097468 @default.
• W2903826135 cites W2016213986 @default.
• W2903826135 cites W2024238985 @default.
• W2903826135 cites W2038218697 @default.
• W2903826135 cites W2045121415 @default.
• W2903826135 cites W2054790877 @default.
• W2903826135 cites W2072347337 @default.
• W2903826135 cites W2078244137 @default.
• W2903826135 cites W2086357633 @default.
• W2903826135 cites W2088715566 @default.
• W2903826135 cites W2109491705 @default.
• W2903826135 cites W2110202168 @default.
• W2903826135 cites W2110768898 @default.
• W2903826135 cites W2112643590 @default.
• W2903826135 cites W2114542846 @default.
• W2903826135 cites W2114745978 @default.
• W2903826135 cites W2116425120 @default.
• W2903826135 cites W2120426523 @default.
• W2903826135 cites W2137839958 @default.
• W2903826135 cites W2142563401 @default.
• W2903826135 cites W2148356388 @default.
• W2903826135 cites W2159803625 @default.
• W2903826135 cites W2165319254 @default.
• W2903826135 cites W2329751835 @default.
• W2903826135 cites W2338563218 @default.
• W2903826135 cites W2518310626 @default.
• W2903826135 doi "https://doi.org/10.1186/s40425-018-0455-2" @default.
• W2903826135 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6292168" @default.
• W2903826135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30541631" @default.
• W2903826135 hasPublicationYear "2018" @default.
• W2903826135 type Work @default.
• W2903826135 sameAs 2903826135 @default.
• W2903826135 citedByCount "47" @default.
• W2903826135 countsByYear W29038261352019 @default.
• W2903826135 countsByYear W29038261352020 @default.
• W2903826135 countsByYear W29038261352021 @default.
• W2903826135 countsByYear W29038261352022 @default.
• W2903826135 countsByYear W29038261352023 @default.
• W2903826135 crossrefType "journal-article" @default.
• W2903826135 hasAuthorship W2903826135A5012656051 @default.
• W2903826135 hasAuthorship W2903826135A5035490415 @default.
• W2903826135 hasAuthorship W2903826135A5035565968 @default.
• W2903826135 hasAuthorship W2903826135A5054122862 @default.
• W2903826135 hasAuthorship W2903826135A5054893411 @default.
• W2903826135 hasAuthorship W2903826135A5061083695 @default.
• W2903826135 hasAuthorship W2903826135A5071090402 @default.
• W2903826135 hasAuthorship W2903826135A5081264511 @default.
• W2903826135 hasAuthorship W2903826135A5087405110 @default.
• W2903826135 hasAuthorship W2903826135A5088802895 @default.
• W2903826135 hasBestOaLocation W29038261351 @default.
• W2903826135 hasConcept C100701293 @default.
• W2903826135 hasConcept C136449434 @default.
• W2903826135 hasConcept C150903083 @default.
• W2903826135 hasConcept C193419808 @default.
• W2903826135 hasConcept C203014093 @default.
• W2903826135 hasConcept C207001950 @default.
• W2903826135 hasConcept C2776090121 @default.
• W2903826135 hasConcept C2776107976 @default.
• W2903826135 hasConcept C2777701055 @default.
• W2903826135 hasConcept C2777863537 @default.
• W2903826135 hasConcept C2778170410 @default.
• W2903826135 hasConcept C2780674031 @default.
• W2903826135 hasConcept C2781236682 @default.
• W2903826135 hasConcept C502942594 @default.
• W2903826135 hasConcept C553184892 @default.
• W2903826135 hasConcept C59822182 @default.
• W2903826135 hasConcept C71924100 @default.
• W2903826135 hasConcept C81444415 @default.
• W2903826135 hasConcept C86803240 @default.
• W2903826135 hasConcept C8891405 @default.
• W2903826135 hasConceptScore W2903826135C100701293 @default.
• W2903826135 hasConceptScore W2903826135C136449434 @default.
• W2903826135 hasConceptScore W2903826135C150903083 @default.
• W2903826135 hasConceptScore W2903826135C193419808 @default.
• W2903826135 hasConceptScore W2903826135C203014093 @default.
• W2903826135 hasConceptScore W2903826135C207001950 @default.
• W2903826135 hasConceptScore W2903826135C2776090121 @default.
• W2903826135 hasConceptScore W2903826135C2776107976 @default.
• W2903826135 hasConceptScore W2903826135C2777701055 @default.

• next